Alnylam pharmaceuticals, inc. (ALNY)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10Sep'09Jun'09
Revenues:
Total revenues

99,476

71,681

70,061

44,714

33,294

21,033

2,069

29,907

21,899

37,924

17,096

15,932

18,960

17,454

13,651

8,709

7,345

7,551

6,324

8,685

18,537

24,019

10,972

7,295

8,275

10,847

8,991

8,687

18,642

8,495

16,759

20,884

20,587

20,455

20,791

20,614

20,897

21,192

27,668

26,617

24,564

24,249

24,601

Operating costs and expenses:
Cost of goods sold

13,302

12,176

5,213

4,326

3,347

-

137

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

169,571

201,301

160,796

163,890

129,127

131,036

139,945

137,582

96,857

117,772

95,252

90,627

86,984

105,011

97,936

83,172

96,273

82,835

68,618

67,007

58,035

55,546

46,273

44,672

43,758

32,106

34,457

24,215

22,179

21,678

22,094

21,723

21,074

23,369

24,274

25,303

26,349

26,080

27,468

28,136

24,700

23,219

38,615

Selling, general and administrative

126,761

156,277

120,351

112,769

89,608

108,688

116,545

84,679

72,447

67,455

47,644

45,779

38,487

27,876

22,391

17,987

21,100

17,228

16,036

14,622

12,724

14,185

9,898

11,518

8,925

8,333

6,768

5,784

6,267

10,166

12,812

11,228

10,406

10,672

8,955

8,429

10,224

7,522

8,928

10,107

11,170

10,680

8,398

Total operating costs and expenses

309,634

369,754

286,360

280,985

222,082

241,389

256,627

222,261

169,304

185,227

142,896

136,406

125,471

132,887

120,327

101,159

117,373

100,063

84,654

81,629

70,759

69,731

56,171

52,300

277,339

40,439

41,225

29,999

28,446

96,844

34,906

32,951

31,480

34,041

33,229

33,732

36,573

33,602

36,396

38,243

35,870

33,899

47,013

In-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-3,890

224,656

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from operations

-210,158

-298,073

-216,299

-236,271

-188,788

-220,356

-254,558

-192,354

-147,405

-147,303

-125,800

-120,474

-106,511

-115,433

-106,676

-92,450

-110,028

-92,512

-78,330

-72,944

-52,222

-45,712

-45,199

-45,005

-269,064

-29,592

-32,234

-21,312

-9,804

-88,349

-18,147

-12,067

-10,893

-13,586

-12,438

-13,118

-15,676

-12,410

-8,728

-11,626

-11,306

-9,650

-22,412

Other income:
Equity in loss of joint venture (Regulus Therapeutics Inc.)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-881

-1,613

-1,139

-889

-954

-467

-1,012

-1,072

-916

-1,226

-3,919

-1,578

-1,136

-816

Interest income

5,480

7,253

9,889

8,781

7,525

10,571

6,796

6,101

5,794

4,235

3,296

2,577

2,128

2,199

2,204

2,092

1,813

1,616

1,610

1,619

1,014

780

753

693

333

285

290

270

224

222

261

271

223

236

265

322

382

472

602

641

590

1,036

1,458

Other income

23,032

14,237

-2,519

-453

43

-1,295

2,925

2,208

335

841

-433

-523

-2,907

300

401

229

5,241

-

-72

-27

-

1,452

524

-77

-82

-29

-12

-11

5

164

-3

-21

191

1

-597

-16

81

1,930

20

43

-11

-10

-24

Change in fair value of liability obligation

-

-

0

9,422

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on litigation settlement

-

-

0

-

-

-

0

20,564

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other income

28,512

21,490

7,370

17,750

7,568

9,276

9,721

28,873

6,129

5,076

2,863

2,054

-779

2,499

2,605

2,321

7,054

1,791

1,538

1,592

1,014

2,232

1,277

616

251

256

278

259

229

15,589

-1,355

-889

-475

-717

-799

-706

-609

5,907

-604

-3,235

-999

-110

618

Loss before income taxes

-181,646

-276,583

-208,929

-218,521

-181,220

-211,080

-244,837

-163,481

-141,276

-142,227

-122,937

-118,420

-107,290

-

-

-

-

-

-

-71,352

-51,208

-43,480

-43,922

-44,389

-268,813

-29,336

-31,956

-21,053

-9,575

-72,760

-19,502

-12,956

-11,368

-

-

-

-

-6,503

-9,332

-14,861

-12,305

-9,760

-21,794

Provision for income taxes

575

-361

-394

960

695

361

445

79

-62

-

-

-

-

-

-

-

-

-

-

431

-431

-22,091

67

-315

-17,870

3,021

-2,270

-2,884

-562

-

-

-

-

-

-

-

-

427

298

-229

18

-552

908

Net loss

-182,221

-276,185

-208,535

-219,481

-181,915

-211,441

-245,282

-163,560

-141,214

-142,227

-122,937

-118,420

-107,290

-112,934

-104,071

-90,129

-102,974

-90,721

-76,792

-71,783

-50,777

-21,389

-43,989

-44,074

-250,943

-32,357

-29,686

-18,169

-9,013

-62,188

-19,502

-12,956

-11,368

-14,303

-13,237

-13,824

-16,285

-6,930

-9,630

-14,632

-12,323

-9,208

-22,702

Net loss per common share - basic and diluted (in dollars per share)

-1.62

-2.44

-1.92

-2.02

-1.73

-2.10

-2.43

-1.63

-1.41

-1.49

-1.34

-1.34

-1.25

-1.32

-1.21

-1.05

-1.21

0.00

-0.91

-0.85

-0.62

0.00

-0.58

-0.58

-3.70

0.00

-0.48

-0.29

-0.15

0.00

-0.38

-0.25

-0.25

0.00

-0.31

-0.33

-0.38

0.00

-0.23

-0.35

-0.29

-0.22

-0.55

Weighted-average common shares used to compute basic and diluted net loss per common share (in shares)

112,748

114,379

108,701

108,576

105,400

101,079

100,783

100,519

99,979

96,263

91,828

88,098

86,027

85,846

85,716

85,545

85,277

84,908

84,633

84,353

82,074

77,083

76,408

75,835

67,786

62,954

62,416

61,661

59,173

52,112

51,542

51,280

46,210

42,262

42,654

42,379

42,345

-

42,123

-

41,870

41,708

41,520

Statements of Comprehensive Loss
Net loss

-182,221

-276,185

-208,535

-219,481

-181,915

-211,441

-245,282

-163,560

-141,214

-142,227

-122,937

-118,420

-107,290

-112,934

-104,071

-90,129

-102,974

-90,721

-76,792

-71,783

-50,777

-21,389

-43,989

-44,074

-250,943

-32,357

-29,686

-18,169

-9,013

-62,188

-19,502

-12,956

-11,368

-14,303

-13,237

-13,824

-16,285

-6,930

-9,630

-14,632

-12,323

-9,208

-22,702

Unrealized gain on marketable debt securities

4,045

-214

-50

462

360

179

415

1,046

-420

-692

218

-476

-1,936

-5,502

1,224

-18,331

-8,224

11,588

-25,981

-33,623

3,622

35,091

-6,230

-3,047

5,313

-7,451

-962

7,309

5,159

15,554

170

-25

128

-14

95

-228

-732

-574

2

492

107

272

1,021

Foreign currency translation

340

-2,624

1,439

842

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-29

-

-4

-23

Defined benefit pension plans, net of tax

-74

-691

-71

4,282

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification adjustment for realized loss on marketable securities included in net loss

-

-

-

-

-

-

-

-

-

0

0

-345

-1,549

161

706

954

5,156

-

-

-

-

-

567

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-177,762

-278,332

-207,075

-222,459

-181,555

-211,262

-244,867

-162,514

-141,634

-142,919

-122,719

-118,551

-107,677

-118,597

-103,553

-109,414

-116,354

-79,133

-102,773

-105,406

-47,155

12,188

-50,786

-47,121

-245,630

-39,808

-30,648

-10,860

-3,854

-46,634

-19,332

-12,981

-11,240

-14,317

-13,142

-14,052

-17,017

-7,504

-9,628

-14,169

-12,216

-8,940

-21,704

Research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,830

2,665

-

2,725

3,246

3,229

3,128

3,248

General and administrative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,384

1,457

-

1,786

1,822

2,098

2,110

2,164

Net product revenues
Total revenues

71,938

55,949

46,066

38,231

26,291

-

460

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net revenues from collaborations
Total revenues

27,538

15,732

23,995

6,483

7,003

8,958

1,609

29,907

21,899

-

17,096

15,932

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-